These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36187106)

  • 1. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
    Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
    Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
    Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
    Losa M; Garbin E; Pedone E; Mortini P
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
    Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
    Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
    Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
    Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report.
    Xiao T; Mao X; Wang O; Yao Y; Deng K; Zhu H; Duan L
    BMC Endocr Disord; 2024 Jul; 24(1):121. PubMed ID: 39044175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
    Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
    Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
    Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
    Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pasireotide in the Personalized Treatment of Acromegaly.
    Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
    Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
    Rak B; Maksymowicz M; Pękul M; Zieliński G
    Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
    Samson SL
    Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
    Araujo-Castro M; Biagetti B; Menéndez Torre E; Novoa-Testa I; Cordido F; Pascual-Corrales E; Rodríguez Berrocal V; Guerrero-Pérez F; Vicente A; Percovich Hualpa JC; García-Centeno R; González-Fernández L; Ollero García MD; Irigaray Echarri A; Moure Rodríguez MD; Novo-Rodríguez C; Calatayud M; Villar-Taibo R; Bernabéu I; Alvarez-Escola C; Benítez Valderrama P; Tenorio-Jiménez C; Abellán Galiana P; Venegas E; González-Molero I; Iglesias P; Blanco-Carrera C; Vidal-Ostos De Lara F; de Miguel Novoa P; López Mezquita E; Hanzu FA; Aldecoa I; Aznar S; Lamas C; Aulinas A; Asla Q; Gracia Gimeno P; Recio-Córdova JM; Avilés-Pérez MD; Asensio-Wandosell D; Sampedro-Núñez M; Cámara R; Paja Fano M; Ruz-Caracuel I; Fajardo C; Marazuela M; Puig-Domingo M
    Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38713182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly.
    Shen M; Chen Z; Shou X; He W; Qiao N; Ma Z; Ye Z; Zhang Y; Zhang Q; Zhou X; Cao X; Zhang Z; Ye H; Li Y; Zhao Y; Li S; He M; Wang Y
    J Neuroendocrinol; 2021 May; 33(5):e12958. PubMed ID: 33998086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].
    Jaquet P; Cortet-Rudelli Ch; Sassolas G; Morange-Ramos I; Chanson P; Brue T; Andrieu JM; Beckers A; Bertherat J; Borson-Chazot F; Brassier G; Caron P; Cogne M; Cottier JP; Delemer B; Dufour H; Enjalbert A; Figarella-Branger D; Gaillard R; Gueydan M; Jan M; Kuhn JM; Raingeard I; Regis J; Roger P; Rohmer V; Sadoul JL; Saveanu A; Tabarin A; Travers N; Trouillas J;
    Ann Endocrinol (Paris); 2003 Dec; 64(6):434-41. PubMed ID: 15067248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
    Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.